Could 100 Be the New 60?
The recent founding of Human Longevity Inc. combined with the groundbreaking work of MYOS could hold the key to longer lifespans.
MYOS Corporation founder Robert Hariri, MD, PhD announced last week the formation of Human Longevity Inc. (HLI), a new company co-founded by Hariri, Peter H. Diamandis, MD and J. Craig Venter, PhD. The new genomics and cell therapy-based diagnostic and therapeutic company is focused solely on finding the answer to aging-related human biological decline. To do so, the HLI team is aiming to build the world’s most comprehensive database on human genotypes and phenotypes. Additionally, they will use analysis of genetic instructions to understand the role of stem cells in disease prevention and maintenance of physical, cognitive and cosmetic vitality.
Hariri’s MYOS research and clinical development program dovetails and will benefit from HLI science. “The MYOS focus on finding ways to treat sarcopenia and support development of lean muscle mass and function throughout a person’s lifespan will be an essential part of sustaining healthy aging,” notes Hariri. “What we learn at MYOS complements the HLI effort to reduce premature death by developing treatments that prevent disease progression at the earlier stage of illness.”